DOCSLIB.ORG

Cardiac Output, Stroke Volume, Total Peripheral Resistance, and Intrathoracic Blood Volume

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cardiac Output, Stroke Volume, Total Peripheral Resistance, and Intrathoracic Blood Volume HEMODYNAMIC CHANGES DURING THIOPENTAL ANESTHESIA IN HUMANS: CARDIAC OUTPUT, STROKE VOLUME, TOTAL PERIPHERAL RESISTANCE, AND INTRATHORACIC BLOOD VOLUME Benjamin Etsten, T. H. Li J Clin Invest. 1955;34(3):500-510. https://doi.org/10.1172/JCI103099. Research Article Find the latest version: https://jci.me/103099/pdf HEMODYNAMIC CHANGES DURING THIOPENTAL ANESTHESIA IN HUMANS: CARDIAC OUTPUT, STROKE VOLUME, TOTAL PERIPHERAL RESISTANCE, AND INTRATHORACIC BLOOD VOLUME 1, 2 By BENJAMIN ETSTEN AND T. H. LI 8 (From the Department of Anesthesia, Tufts College Medical School and New England Center Hospital, Boston, Mass.) (Submitted for publication August 13, 1954; accepted November 24, 1954) Thiopental, monosodium 5-ethyl-5- (1-methyl- the patient was brought to a quiet anesthesia preparation butyl) -thiobarbiturate, is extensively used in room for study and was placed in the supine position clinical anesthesia either as a primary with one arm resting on a pillow above the angle of anesthetic Louis. A 15-gauge needle was placed in the median agent for short surgical procedures or as a sup- basilic vein of the elevated arm and was connected with plementary drug in conjunction with other anes- a three-way stopcock for the administration of T-1824 thetics. Fatalities have been attributed to its use (Evans Blue) and thiopental. A thin-walled 18-gauge (1, 2) and cardiac arrest has occurred following needle with stylet was inserted into the brachial artery of its administration to patients under spinal anes- the other arm for the collection of blood samples. Elec- trocardiograph electrodes were appropriately placed and thesia (3). electroencephalograph electrodes were positioned accord- Most of the information concerning the cardio- ing to the method of Kiersey, Bickford, and Faulconer circulatory effects of thiopental has been derived (8). from animal experimentation (4, 5). Although Control observations were made after a steady rest- there have been numerous clinical reports de- ing state was maintained for at least 30 minutes. It was considered that a basal resting state was obtained only scribing changes in blood pressure, pulse rate when the pulse rate was below 84 per minute. An in- and respiration during its administration, quanti- travenous drip of 0.2 per cent thiopental was adminis- tative investigations on the effect of this agent on tered slowly. The rate of flow was adjusted to produce the cardiocirculatory dynamics in man are meagre specific levels of anesthesia as defined by Kiersey, Bick- (6, 7). In view of its extensive use and the com- ford, and Faulconer (8) and monitored by continuous EEG tracings. The observations were correlated ac- plications ascribed to its administration, a critical cording to the specific levels of narcosis as shown in the analysis of the hemodynamic changes which occur following classification: at various levels of thiopental narcosis in patients prior to surgery will form the basis of this com- E.E.G. Pattern Level of Anesthesia 0 Control munication. I Hypnosis METHOD II Light III and IV Deep Cardiac output and related hemodynamic determina- tions were obtained on 14 patients prior to surgery. The average duration of each study was two hours and These subjects were in good physical condition and had the total dosage of thiopental ranged from 0.6 to 1.0 gm.; no discernible cardiovascular or pulmonary disease (aver- 100 per cent oxygen was administered throughout the age age-41 years; range 14 to 60 years). The pre- procedure. anesthetic dosage of morphine and scopolamine varied After specific levels of thiopental anesthesia were according to the age, weight, and physical status. Ninety maintained for 15 minutes, the following observations minutes after a subcutaneous administration of morphine were made: cardiac output, mean arterial pressure, total (5.4 to 8.0 mgm.) and scopolamine (0.26 to 0.43 mgm.), peripheral resistance, stroke volume, mean circulation time, intrathoracic blood volume, arterial oxygen con- 'Aided by a research grant from the National Insti- tent and capacity, carbon dioxide content and pH, and tutes of Health, U. S. Public Health Service, No. H-1711 electrocardiographic recording. (C2). The cardiac output was determined by the dye dilution 2A preliminary report was presented at the meeting of technique (9). The injection of T-1824 in a 0.5 per the Federation of American Societies for Experimental cent solution and collection of samples from the brachial Biology, Atlantic City, New Jersey, April 16, 1954. artery were carried out according to the modified 8 Charlton Fellow-Tufts College Medical School. method of Etsten, Li, and Fisher (10, 11). The stand- 500 HEMODYNAMICS DURING THIOPENTAL ANESTHESIA 501 ard deviation of the difference between the Fick and dye curve until recirculation appears. The last term methods was 12.7 per cent, and the standard deviation CK+1 (TK+1 + rL) equals the sum of the products for the difference of duplicate values of cardiac indexes by the modified dye technique was 2.4 per cent (10, 11). of all extrapolated terms multiplied by time. Brachial arterial pressure was measured by means of a The mean circulation time was determined by plotting Statham strain gauge (model P-23A) and continuously on semi-logarithmic graph paper the concentration of recorded on a multi-channel, direct-writing oscillograph the dye in each sample against the time of collection of with a frequency response of 60 C.P.S. The mean ar- the sample. The mean circulation time is in close agree- terial pressure was determined by planimetry of the pulse ment to a vertical line that divides the area subtended by wave. Samples of arterial blood were drawn immediately the primary dye curve into two equal parts. after the cardiac output determination for analysis of 3. Intrathoracic blood volume (15, 16): The volume oxygen content and capacity, carbon dioxide content, and calculated from the mean circulation time X repre- pH (Cambridge Electron Ray pH Meter-Research C6O. Model). Values of the pH were accepted when the du- sents the volume of circulating blood from the point of plicates checked within a 0.02 unit. The carbon dioxide injection of the dye in the peripheral arm veins, right tension was calculated from the carbon dioxide serum heart, pulmonary vasculature, the left heart and the ar- content and pH values using the nomogram of Peters teries to the point of sampling. and Van Slyke (12). The hematocrit was determined Intrathoracic blood volume (liters) = C XO.X M.C.T., by centrifuging the heparinized blood in Wintrobe tubes. 60 The following values were calculated from the formulae: where C.O. = cardiac output in L. per min. and M.C.T. = 1. Cardiac output: The cardiac output was calculated mean circulation time in seconds. Changes of the intra- from the dye dilution curve according to the modified thoracic blood volume were not considered as significant method of Hamilton, Moore, Kinsman, and Spurling when they were less than 15 per cent of the control val- ues (7, 17). 60X 10 (10, 13): F = s X 00 -H~ : F represents the car- 4. Total peripheral resistance: diac output in liters per minute, I the amount of in- T.P.R( dYnes- sec.) jected dye in mgm., H the hematocrit (not corrected for trapped plasma) and S the sum of all the dye concen- Mean arterial blood pres. (mm. Hg) X 1,332 trations in the primary circulation taken at 1-second C.O. (cc./sec.) intervals. The gradient was represented by the arterial pressure A semi-log plot is made from the experimental data only, since it has been found that the right auricular and the value of S is obtained in the following manner pressure is unchanged during thiopental anesthesia (18). (10, 11, 14): S = A + B. A equals the sum of CQ + C2 + 5. Left ventricular work: ... CK, i.e., all dye concentrations in mgm. per liter ex- L.V.W (Kg.-meters per min.) = 0.0135 X C.O. (L. per cept the last term on the descending limb of the primary min.) X mean arterial blood pressure (mm. Hg) curve before recirculation starts. This last term is 6. Statistical analysis: The per cent change refers to designated CK+1, and CK is the one just prior to this the mean per cent change of each group. Each patient last term. A straight line is extrapolated from CG, and served as his own control. Only the control values for B equals the sum of the concentrations obtained from the those patients studied under a specific level of anesthesia extrapolated portion of the descending limb of the curve. were used to calculate the per cent change found during The last three or more points of the primary circula- that specific level. The mean of the control values for tion fall on a straight line corresponding to an exponen- the whole group was not used to calculate the per cent tial fall in dye concentration. From these few points a change found during any specific level of anesthesia since straight line is extrapolated to complete the graph of some patients were not studied throughout all of the the primary circulation. The sum of the dye concentra- levels. tions in this extrapolated portion of the graph is com- The probability or "P" value was obtained by the method of the Fisher's T-test. puted by the formula for geometric series. B = IC+1 and is added to the sum of A; r is the ratio of any term RESULTS of the series to the preceding term. 2. Mean circulation time: The mean circulation time The pertinent data are summarized in Table I; is the time taken by the dye particle of average speed to the mean, the standard deviation, and the stand- pass through the veins from the point of injection, the right heart, the lungs, the left heart, and the arteries to ard error of the mean of the absolute values are the point of sampling.
Load more

Recommended publications
  • Pharmaceutical Starting Materials/Essential Drugs
    BULLETIN MNS October 2009 PHARMACEUTICAL STARTING MATERIALS MARKET NEWS SERVICE (MNS) BI -MONTHLY EDITION Market News Service Pharmaceutical Starting Materials/Essential Drugs October 2009, Issue 5 The Market News Service (MNS) is made available free of charge to all Trade Support Institutions and enterprises in Sub-Saharan African countries under a joint programme of the International Trade Centre and CBI, the Dutch Centre for the Promotion of Imports from Developing Countries (www.cbi.nl). Should you be interested in becoming an information provider and contributing to MNS' efforts to improve market transparency and facilitate trade, please contact us at [email protected]. This issue continues the series, started at the beginning of the year, focusing on the leading markets in various world regions. This issue covers the trends and recent developments in eastern European pharmaceutical markets. To subscribe to the report or to access MNS reports directly online, please contact [email protected] or visit our website at: http://www.intracen.org/mns. Copyright © MNS/ITC 2007. All rights reserved 1 Market News Service Pharmaceutical Starting Materials Introduction WHAT IS THE MNS FOR PHARMACEUTICAL STARTING MATERIALS/ESSENTIAL DRUGS? In 1986, the World Health Assembly laid before the Organization the responsibility to provide price information on pharmaceutical starting materials. WHA 39.27 endorsed WHO‟s revised drug strategy, which states “... strengthen market intelligence; support drug procurement by developing countries...” The responsibility was reaffirmed at the 49th WHA in 1996. Resolution WHA 49.14 requests the Director General, under paragraph 2(6) “to strengthen market intelligence, review in collaboration with interested parties‟ information on prices and sources of information on prices of essential drugs and starting material of good quality, which meet requirements of internationally recognized pharmacopoeias or equivalent regulatory standards, and provide this information to member states”.
    [Show full text]
  • Cyclopropane Anaesthesia by JOHN BOYD, M.D., D.A
    Cyclopropane Anaesthesia By JOHN BOYD, M.D., D.A. TLHIS paper is based on my experience of one thousand cases of cyclopropane anaesthesia personally conducted by me since October, 1938, both in hospital and in private. But before discussing these it might be convenient for me to mention here something about the drug itself. HISTORY. Cyclopropane was first isolated in Germany in 1882 by Freund, who also demonstrated its chemical structure, C3H6. He did not, however, describe its anaesthetic properties. Following its discovery it seems to have been forgotten until 1928, when Henderson and Lucas of Toronto, in investigating contaminants of propylene, another anesthetic with undesirable side-effects, and itself'an isomer of cyclopropane, found that the supposed cause of the cardiac disturbances was in reality a better and less toxic anaesthetic. They demonstrated its anaesthetic properties first on animals, and then, before releasing it to the medical profession for clinical trial, they anaesthetised each other, and determined the quantities necessary for administration to man. In 1933 the first clinical trials of cyclopropane were made by Waters and his associates of the University of Wisconsin. In October of that year Waters presented a preliminary report on its anaesthetic properties in man,1 confirming the findings of Henderson and Lucas. Rowbotham introduced it to England first in 1935, and since then its use has spread rapidly throughout the country. PREPARATION. Cyclopropane is prepared commercially by the reduction of trimethylene bromide in the presence of metallic zinc in ethyl alcohol. It is also made commercially from propane in natural gas by progressive thermal chlorination.
    [Show full text]
  • Unnamed Document
    Mutations M287L and Q266I in the Glycine Receptor ␣1 Subunit Change Sensitivity to Volatile Anesthetics in Oocytes and Neurons, but Not the Minimal Alveolar Concentration in Knockin Mice Cecilia M. Borghese, Ph.D.,* Wei Xiong, Ph.D.,† S. Irene Oh, B.S.,‡ Angel Ho, B.S.,§ S. John Mihic, Ph.D.,ʈ Li Zhang, M.D.,# David M. Lovinger, Ph.D.,** Gregg E. Homanics, Ph.D.,†† Edmond I. Eger 2nd, M.D.,‡‡ R. Adron Harris, Ph.D.§§ ABSTRACT What We Already Know about This Topic • Inhibitory spinal glycine receptor function is enhanced by vol- Background: Volatile anesthetics (VAs) alter the function of atile anesthetics, making this a leading candidate for their key central nervous system proteins but it is not clear which, immobilizing effect if any, of these targets mediates the immobility produced by • Point mutations in the ␣1 subunit of glycine receptors have been identified that increase or decrease receptor potentiation VAs in the face of noxious stimulation. A leading candidate is by volatile anesthetics the glycine receptor, a ligand-gated ion channel important for spinal physiology. VAs variously enhance such function, and blockade of spinal glycine receptors with strychnine af- fects the minimal alveolar concentration (an anesthetic What This Article Tells Us That Is New EC50) in proportion to the degree of enhancement. • Mice harboring specific mutations in their glycine receptors Methods: We produced single amino acid mutations into that increased or decreased potentiation by volatile anesthetic in vitro did not have significantly altered changes in anesthetic the glycine receptor ␣1 subunit that increased (M287L, third potency in vivo transmembrane region) or decreased (Q266I, second trans- • These findings indicate that this glycine receptor does not me- membrane region) sensitivity to isoflurane in recombinant diate anesthetic immobility, and that other targets must be receptors, and introduced such receptors into mice.
    [Show full text]
  • Blood Vessels: Part A
    Chapter 19 The Cardiovascular System: Blood Vessels: Part A Blood Vessels • Delivery system of dynamic structures that begins and ends at heart – Arteries: carry blood away from heart; oxygenated except for pulmonary circulation and umbilical vessels of fetus – Capillaries: contact tissue cells; directly serve cellular needs – Veins: carry blood toward heart Structure of Blood Vessel Walls • Lumen – Central blood-containing space • Three wall layers in arteries and veins – Tunica intima, tunica media, and tunica externa • Capillaries – Endothelium with sparse basal lamina Tunics • Tunica intima – Endothelium lines lumen of all vessels • Continuous with endocardium • Slick surface reduces friction – Subendothelial layer in vessels larger than 1 mm; connective tissue basement membrane Tunics • Tunica media – Smooth muscle and sheets of elastin – Sympathetic vasomotor nerve fibers control vasoconstriction and vasodilation of vessels • Influence blood flow and blood pressure Tunics • Tunica externa (tunica adventitia) – Collagen fibers protect and reinforce; anchor to surrounding structures – Contains nerve fibers, lymphatic vessels – Vasa vasorum of larger vessels nourishes external layer Blood Vessels • Vessels vary in length, diameter, wall thickness, tissue makeup • See figure 19.2 for interaction with lymphatic vessels Arterial System: Elastic Arteries • Large thick-walled arteries with elastin in all three tunics • Aorta and its major branches • Large lumen offers low resistance • Inactive in vasoconstriction • Act as pressure reservoirs—expand
    [Show full text]
  • Cyclobutane Derivatives in Drug Discovery
    Cyclobutane Derivatives in Drug Discovery Overview Key Points Unlike larger and conformationally flexible cycloalkanes, Cyclobutane adopts a rigid cyclobutane and cyclopropane have rigid conformations. Due to the ring strain, cyclobutane adopts a rigid puckered puckered conformation Offer ing advantages on (~30°) conformation. This unique architecture bestowed potency, selectivity and certain cyclobutane-containing drugs with unique pharmacokinetic (PK) properties. When applied appropriately, cyclobutyl profile. scaffolds may offer advantages on potency, selectivity and pharmacokinetic (PK) profile. Bridging Molecules for Innovative Medicines 1 PharmaBlock designs and Cyclobutane-containing Drugs synthesizes over 1846 At least four cyclobutane-containing drugs are currently on the market. cyclobutanes, and 497 Chemotherapy carboplatin (Paraplatin, 1) for treating ovarian cancer was cyclobutane products are prepared to lower the strong nephrotoxicity associated with cisplatin. By in stock. CLICK HERE to replacing cisplatin’s two chlorine atoms with cyclobutane-1,1-dicarboxylic find detailed product acid, carboplatin (1) has a much lower nephrotoxicity than cisplatin. On information on webpage. the other hand, Schering-Plough/Merck’s hepatitis C virus (HCV) NS3/4A protease inhibitor boceprevir (Victrelis, 2) also contains a cyclobutane group in its P1 region. It is 3- and 19-fold more potent than the 1 corresponding cyclopropyl and cyclopentyl analogues, respectively. Androgen receptor (AR) antagonist apalutamide (Erleada, 4) for treating castration-resistant prostate cancer (CRPC) has a spirocyclic cyclobutane scaffold. It is in the same series as enzalutamide (Xtandi, 3) discovered by Jung’s group at UCLA in the 2000s. The cyclobutyl- (4) and cyclopentyl- derivative have activities comparable to the dimethyl analogue although the corresponding six-, seven-, and eight-membered rings are slightly less 2 active.
    [Show full text]
  • The Icefish (Chionodraco Hamatus)
    The Journal of Experimental Biology 207, 3855-3864 3855 Published by The Company of Biologists 2004 doi:10.1242/jeb.01180 No hemoglobin but NO: the icefish (Chionodraco hamatus) heart as a paradigm D. Pellegrino1,2, C. A. Palmerini3 and B. Tota2,4,* Departments of 1Pharmaco-Biology and 2Cellular Biology, University of Calabria, 87030, Arcavacata di Rende, CS, Italy, 3Department of Cellular and Molecular Biology, University of Perugia, 06126, Perugia, Italy and 4Zoological Station ‘A. Dohrn’, Villa Comunale, 80121, Napoli, Italy *Author for correspondence (e-mail: [email protected]) Accepted 13 July 2004 Summary The role of nitric oxide (NO) in cardio-vascular therefore demonstrate that under basal working homeostasis is now known to include allosteric redox conditions the icefish heart is under the tonic influence modulation of cell respiration. An interesting animal for of a NO-cGMP-mediated positive inotropism. We also the study of this wide-ranging influence of NO is the cold- show that the working heart, which has intracardiac adapted Antarctic icefish Chionodraco hamatus, which is NOS (shown by NADPH-diaphorase activity and characterised by evolutionary loss of hemoglobin and immunolocalization), can produce and release NO, as multiple cardio-circulatory and subcellular compensations measured by nitrite appearance in the cardiac effluent. for efficient oxygen delivery. Using an isolated, perfused These results indicate the presence of a functional NOS working heart preparation of C. hamatus, we show that system in the icefish heart, possibly serving a both endogenous (L-arginine) and exogenous (SIN-1 in paracrine/autocrine regulatory role. presence of SOD) NO-donors as well as the guanylate cyclase (GC) donor 8Br-cGMP elicit positive inotropism, while both nitric oxide synthase (NOS) and sGC Key words: nitric oxide, heart, Antarctic teleost, icefish, Chionodraco inhibitors, i.e.
    [Show full text]
  • Euthanasia of Experimental Animals
    EUTHANASIA OF EXPERIMENTAL ANIMALS • *• • • • • • • *•* EUROPEAN 1COMMISSIO N This document has been prepared for use within the Commission. It does not necessarily represent the Commission's official position. A great deal of additional information on the European Union is available on the Internet. It can be accessed through the Europa server (http://europa.eu.int) Cataloguing data can be found at the end of this publication Luxembourg: Office for Official Publications of the European Communities, 1997 ISBN 92-827-9694-9 © European Communities, 1997 Reproduction is authorized, except for commercial purposes, provided the source is acknowledged Printed in Belgium European Commission EUTHANASIA OF EXPERIMENTAL ANIMALS Document EUTHANASIA OF EXPERIMENTAL ANIMALS Report prepared for the European Commission by Mrs Bryony Close Dr Keith Banister Dr Vera Baumans Dr Eva-Maria Bernoth Dr Niall Bromage Dr John Bunyan Professor Dr Wolff Erhardt Professor Paul Flecknell Dr Neville Gregory Professor Dr Hansjoachim Hackbarth Professor David Morton Mr Clifford Warwick EUTHANASIA OF EXPERIMENTAL ANIMALS CONTENTS Page Preface 1 Acknowledgements 2 1. Introduction 3 1.1 Objectives of euthanasia 3 1.2 Definition of terms 3 1.3 Signs of pain and distress 4 1.4 Recognition and confirmation of death 5 1.5 Personnel and training 5 1.6 Handling and restraint 6 1.7 Equipment 6 1.8 Carcass and waste disposal 6 2. General comments on methods of euthanasia 7 2.1 Acceptable methods of euthanasia 7 2.2 Methods acceptable for unconscious animals 15 2.3 Methods that are not acceptable for euthanasia 16 3. Methods of euthanasia for each species group 21 3.1 Fish 21 3.2 Amphibians 27 3.3 Reptiles 31 3.4 Birds 35 3.5 Rodents 41 3.6 Rabbits 47 3.7 Carnivores - dogs, cats, ferrets 53 3.8 Large mammals - pigs, sheep, goats, cattle, horses 57 3.9 Non-human primates 61 3.10 Other animals not commonly used for experiments 62 4.
    [Show full text]
  • Pharmacology – Inhalant Anesthetics
    Pharmacology- Inhalant Anesthetics Lyon Lee DVM PhD DACVA Introduction • Maintenance of general anesthesia is primarily carried out using inhalation anesthetics, although intravenous anesthetics may be used for short procedures. • Inhalation anesthetics provide quicker changes of anesthetic depth than injectable anesthetics, and reversal of central nervous depression is more readily achieved, explaining for its popularity in prolonged anesthesia (less risk of overdosing, less accumulation and quicker recovery) (see table 1) Table 1. Comparison of inhalant and injectable anesthetics Inhalant Technique Injectable Technique Expensive Equipment Cheap (needles, syringes) Patent Airway and high O2 Not necessarily Better control of anesthetic depth Once given, suffer the consequences Ease of elimination (ventilation) Only through metabolism & Excretion Pollution No • Commonly administered inhalant anesthetics include volatile liquids such as isoflurane, halothane, sevoflurane and desflurane, and inorganic gas, nitrous oxide (N2O). Except N2O, these volatile anesthetics are chemically ‘halogenated hydrocarbons’ and all are closely related. • Physical characteristics of volatile anesthetics govern their clinical effects and practicality associated with their use. Table 2. Physical characteristics of some volatile anesthetic agents. (MAC is for man) Name partition coefficient. boiling point MAC % blood /gas oil/gas (deg=C) Nitrous oxide 0.47 1.4 -89 105 Cyclopropane 0.55 11.5 -34 9.2 Halothane 2.4 220 50.2 0.75 Methoxyflurane 11.0 950 104.7 0.2 Enflurane 1.9 98 56.5 1.68 Isoflurane 1.4 97 48.5 1.15 Sevoflurane 0.6 53 58.5 2.5 Desflurane 0.42 18.7 25 5.72 Diethyl ether 12 65 34.6 1.92 Chloroform 8 400 61.2 0.77 Trichloroethylene 9 714 86.7 0.23 • The volatile anesthetics are administered as vapors after their evaporization in devices known as vaporizers.
    [Show full text]
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS
    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
    [Show full text]
  • A Review of the Stroke Volume Response to Upright Exercise in Healthy Subjects
    190 Br J Sports Med: first published as 10.1136/bjsm.2004.013037 on 25 March 2005. Downloaded from REVIEW A review of the stroke volume response to upright exercise in healthy subjects C A Vella, R A Robergs ............................................................................................................................... Br J Sports Med 2005;39:190–195. doi: 10.1136/bjsm.2004.013037 Traditionally, it has been accepted that, during incremental well trained athletes (subject sex was not stated). Unfortunately, these findings were exercise, stroke volume plateaus at 40% of VO2MAX. largely ignored and it became accepted that However, recent research has documented that stroke stroke volume plateaus during exercise of increasing intensity. volume progressively increases to VO2MAX in both trained More recent investigations have reported that and untrained subjects. The stroke volume response to stroke volume progressively increases in certain 7–12 incremental exercise to VO2MAX may be influenced by people. The mechanisms for the continual training status, age, and sex. For endurance trained increase in stroke volume are not completely understood. Gledhill et al7 proposed that subjects, the proposed mechanisms for the progressive enhanced diastolic filling and subsequent increase in stroke volume to VO2MAX are enhanced diastolic enhanced contractility are responsible for the filling, enhanced contractility, larger blood volume, and increased stroke volume in trained subjects. However, an increase in stroke volume with an decreased cardiac afterload. For untrained subjects, it has increase in exercise intensity has also been been proposed that continued increases in stroke volume reported in untrained subjects.89Table 1 presents may result from a naturally occurring high blood volume. a summary of the past research that has quantified stroke volume during exercise.
    [Show full text]
  • Effects of Vasodilation and Arterial Resistance on Cardiac Output Aliya Siddiqui Department of Biotechnology, Chaitanya P.G
    & Experim l e ca n i t in a l l C Aliya, J Clinic Experiment Cardiol 2011, 2:11 C f a Journal of Clinical & Experimental o r d l DOI: 10.4172/2155-9880.1000170 i a o n l o r g u y o J Cardiology ISSN: 2155-9880 Review Article Open Access Effects of Vasodilation and Arterial Resistance on Cardiac Output Aliya Siddiqui Department of Biotechnology, Chaitanya P.G. College, Kakatiya University, Warangal, India Abstract Heart is one of the most important organs present in human body which pumps blood throughout the body using blood vessels. With each heartbeat, blood is sent throughout the body, carrying oxygen and nutrients to all the cells in body. The cardiac cycle is the sequence of events that occurs when the heart beats. Blood pressure is maximum during systole, when the heart is pushing and minimum during diastole, when the heart is relaxed. Vasodilation caused by relaxation of smooth muscle cells in arteries causes an increase in blood flow. When blood vessels dilate, the blood flow is increased due to a decrease in vascular resistance. Therefore, dilation of arteries and arterioles leads to an immediate decrease in arterial blood pressure and heart rate. Cardiac output is the amount of blood ejected by the left ventricle in one minute. Cardiac output (CO) is the volume of blood being pumped by the heart, by left ventricle in the time interval of one minute. The effects of vasodilation, how the blood quantity increases and decreases along with the blood flow and the arterial blood flow and resistance on cardiac output is discussed in this reviewArticle.
    [Show full text]
  • DOCUMENT RESUME ED 300 697 CG 021 192 AUTHOR Gougelet, Robert M.; Nelson, E. Don TITLE Alcohol and Other Chemicals. Adolescent A
    DOCUMENT RESUME ED 300 697 CG 021 192 AUTHOR Gougelet, Robert M.; Nelson, E. Don TITLE Alcohol and Other Chemicals. Adolescent Alcoholism: Recognizing, Intervening, and Treating Series No. 6. INSTITUTION Ohio State Univ., Columbus. Dept. of Family Medicine. SPONS AGENCY Health Resources and Services Administration (DHHS/PHS), Rockville, MD. Bureau of Health Professions. PUB DATE 87 CONTRACT 240-83-0094 NOTE 30p.; For other guides in this series, see CG 021 187-193. AVAILABLE FROMDepartment of Family Medicine, The Ohio State University, Columbus, OH 43210 ($5.00 each, set of seven, $25.00; audiocassette of series, $15.00; set of four videotapes keyed to guides, $165.00 half-inch tape, $225.00 three-quarter inch tape; all orders prepaid). PUB TYPE Guides - Classroom Use - Materials (For Learner) (051) -- Reports - General (140) EDRS PRICE MF01 Plus Plstage. PC Not Available from EDRS. DESCRIPTORS *Adolescents; *Alcoholism; *Clinical Diagnosis; *Drug Use; *Family Problems; Physician Patient Relationship; *Physicians; Substance Abuse; Units of Study ABSTRACT This document is one of seven publications contained in a series of materials for physicians on recognizing, intervening with, and treating adolescent alcoholism. The materials in this unit of study are designed to help the physician know the different classes of drugs, recognize common presenting symptoms of drug overdose, and place use and abuse in context. To do this, drug characteristics and pathophysiological and psychological effects of drugs are examined as they relate to administration,
    [Show full text]